Translate page

  • Presentations from the EHA2022 Congress

  • EHA 2022: Mechanisms of disease progression in chronic myeloid leukemia (S. Tiong Ong)

  • EHA 2022: Non-BCR-ABL1 biomarkers of prognosis in CML (Shady Awad)

  • COLT Meeting 2019: CML related topics

  • COLT Meeting 2019: The CML frontier

    iCMLf Forum 2015 Webstreams

    Forum 2015 Speakers red

    Webstreams of the presentations from the iCMLf Forum for Physicians from Emerging Regions 2015 are now available to view. Presenters give the local perspectives on each topic followed by discussion with the audience and iCMLf experts.

    View the practicalities of:

    1. Managing children with CML 
      Professor Deepak Bansal (India) and Professor Meinolf Suttorp (Germany)
    2. Practicalities treating CML with generic therapies 
      Dr Carolina Pavlovsky (Argentina) and Professor Jeff Lipton (Canada)
    3. Challenges with long term CML therapy
      Professor Qian Jiang (China) and Professor Michael Mauro (USA)

    Click on the presentations below to view the webstreams and see the slides.
    (We are very grateful for the support of Brandcast media to produce these web streams) 



    Forum 2015 Bansal II red

    Prof. Deepak Bansal
    Chandigarh, India

    Managing children with CML - Perspectives from India 

    Topics include; treatment of children with CML in India, main characteristics of managing children with CML in India, key challenges to meet.






    Forum 2015 Suttorp red

    Prof. Meinolf Suttorp
    Dresden, Germany

    Managing children with CML 

    Topics include; managing children with CML in Europe and globally, problems with adherence in adolescent patients, reducing side effects, applying adult CML scores to pediatric patients.





    Forum 2015 Pavlovsky red

    Dr Carolina Pavlovsky
    Fundaleu, Argentina

    The practicalities of treating CML with generic therapies -
    Perspectives from Argentina

    Topics include; generics in Argentina, responses in CML patients with generic therapy, adverse events in patients with generic imatinib, pro's/con's of non-branded drugs. 





    Forum 2015 Lipton redProf. Jeff Lipton
    Toronto, Canada

    The practicalities of treating CML with generic therapies

    - Experience and recommendations 

    Topics include; experiences with generic TKI's in Canada, key recommendations for treating CML with generics.






    Forum 2015 Jiang II redProf. Qian Jiang
    Beijing, China

    Challenges with long-term CML therapy - Perspectives from China

    Topics include; CML therapy in China, patient-assistance programs, therapy goals & preference for discontinuing therapy, long-term CML therapy: issues & solutions. 






    Forum 2015 Mauro red
    Prof. Michael Mauro
    New York, USA

    Managing the 'c' in Chronic Myeloid Leukemia 

    Topics include: putting CML response into perspective, putting CML cost into perspective, how close can we come with 'optimized' imatinib?, defining a standard of TKI discontinuation studies.